Shah, Jessica StukelMacaitis, JosephLundquist, BridneyJohnstone, BrianColeman, MichaelJefferson, Michelle A.Glaser, JacobRodriguez, Annette R.Cardin, SylvainWang, Heuy-ChingBurdette, Alexander2023-09-072023-09-072022-10-21Shah JS, Macaitis J, Lundquist B, et al. Evaluating Thera-101 as a Low-Volume Resuscitation Fluid in a Model of Polytrauma. Int J Mol Sci. 2022;23(20):12664. Published 2022 Oct 21. doi:10.3390/ijms232012664https://hdl.handle.net/1805/35468Traumatic brain injury (TBI) and hemorrhage remain challenging to treat in austere conditions. Developing a therapeutic to mitigate the associated pathophysiology is critical to meet this treatment gap, especially as these injuries and associated high mortality are possibly preventable. Here, Thera-101 (T-101) was evaluated as low-volume resuscitative fluid in a rat model of TBI and hemorrhage. The therapeutic, T-101, is uniquely situated as a TBI and hemorrhage intervention. It contains a cocktail of proteins and microvesicles from the secretome of adipose-derived mesenchymal stromal cells that can act on repair and regenerative mechanisms associated with poly-trauma. T-101 efficacy was determined at 4, 24, 48, and 72 h post-injury by evaluating blood chemistry, inflammatory chemo/cytokines, histology, and diffusion tensor imaging. Blood chemistry indicated that T-101 reduced the markers of liver damage to Sham levels while the levels remained elevated with the control (saline) resuscitative fluid. Histology supports the potential protective effects of T-101 on the kidneys. Diffusion tensor imaging showed that the injury caused the most damage to the corpus callosum and the fimbria. Immunohistochemistry suggests that T-101 may mitigate astrocyte activation at 72 h. Together, these data suggest that T-101 may serve as a potential field deployable low-volume resuscitation therapeutic.en-USAttribution 4.0 InternationalSecretomeCell-based therapyTraumaNeuroprotectionOrgan damageArticle